132 / 510
Cuidados
Continuos
131
BIBLIOGRAFÍA
Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease
and benefits of thromboprophylaxis. Cancer. 201;117:1334-49.
Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with
cancer. J Clin Oncol. 2009;27:4839-47.
Khorana AA, AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation
of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-7.
Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A. Duration of
prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N
Engl J Med. 2002;346:975-80.
Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with
malignancy. J Clin Oncol. 2009;27:4858-64.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al. Venous
thromboembolism prophylaxis and treatment in patients with cancer: American Society of
Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189-204.
Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, et al. Anticoagulation for the initial
treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011
Jun 15;(6):CD006649.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low molecular weight
heparin versus a coumarin for the prevention of recurrent venous thromboembolism in
patients with cancer. N Engl J Med. 2003:349:146-53.
Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-
molecular-weight heparinandwarfarin for the secondary preventionof venous thromboembolism
in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-35.
Deitcher SR, Kessler CM, MerliG, Rigas JR, Lyons RM, Fareed J. ONCENOX Investigators.
Secondary prevention of venous thromboembolic events in patients with active cancer:
enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl
Thromb Hemost. 2006;12:389-96.
Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-
weight heparin
versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119:1062-72.
Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial
of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.
Lancet. 1997;349:759-762.
Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, et al. Development
of a clinical prediction rule for risk stratifi cation of recurrent venous thromboembolism in
patients with cancer associated venous thromboembolism. Circulation. 2012;126:448-54.
14 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous
thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary
embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29:2405-9.
PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava fi lters in the
prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire
par Interruption Cave) randomized study. Circulation. 2005;112:416-22.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.